Related Experiment Video
Updated: Jun 18, 2026
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Miglustat therapy in juvenile Sandhoff disease
1Department of Neurology, Ullevål University Hospital, Oslo and Faculty of Medicine, University of Oslo, 0407, Oslo, Norway. chantal.tallaksen@ulleval.no
Journal of Inherited Metabolic Disease
|November 10, 2009
Summary
This case report suggests miglustat may slow Sandhoff disease progression in juvenile patients. Electroconvulsive therapy also helped manage depressive symptoms in this rare inherited metabolic disorder.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- GM(2)-gangliosidosis, including Sandhoff disease, is a rare inherited metabolic disorder caused by beta-hexosaminidase gene mutations.
- It leads to GM(2) ganglioside accumulation, primarily in the central nervous system, causing progressive neurological decline.
- Currently, no definitive treatments exist, with management limited to palliative care.
Observation:
- A Norwegian adolescent diagnosed with Sandhoff disease presented with ataxia, dysarthria, and later depression and weight loss.
- The patient received miglustat, a glucosylceramide synthase inhibitor, for 2.5 years.
- Electroconvulsive therapy (ECT) was administered to manage depressive symptoms.
Findings:
- Miglustat treatment appeared to stabilize body weight and slow disease progression, indicated by a lack of further brain atrophy.
- ECT effectively alleviated depressive symptoms and improved overall functioning.
- This case highlights potential therapeutic benefits of miglustat in juvenile Sandhoff disease.
Implications:
- Miglustat shows promise as a treatment for juvenile Sandhoff disease, potentially slowing neurological deterioration.
- ECT can be a valuable adjunctive therapy for managing psychiatric manifestations in Sandhoff disease patients.
- Further research into miglustat and combined therapies is warranted for lysosomal storage diseases.
Related Concept Videos
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...